Search
Now showing items 1-2 of 2
Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial
(Elsevier, 2022-04-20)
Background WHO guidelines recommend dolutegravir plus two nucleoside reverse transcriptase inhibitors (NRTIs)
for second-line HIV therapy, with NRTI switching from first-line tenofovir to zidovudine. We aimed to ...
“You would not be in a hurry to go back home”: Patients’ willingness to participate in HIV/AIDS clinical trials at a clinical and research facility in Kampala, Uganda
(BMC, 2020)
Background: Few studies have examined factors associated with willingness of people living with HIV (PLHIV) to
participate in HIV treatment clinical trials in Sub-Saharan Africa. We assessed the factors associated with ...